Combination of Mesothelin and CEA Significantly Improves the Differentiation between Malignant Pleural Mesothelioma, Benign Asbestos Disease, and Lung Cancer
- 1 July 2013
- journal article
- research article
- Published by Elsevier in Journal of Thoracic Oncology
- Vol. 8 (7) , 947-951
Abstract
No abstract availableKeywords
This publication has 15 references indexed in Scilit:
- Serum Mesothelin for Diagnosing Malignant Pleural Mesothelioma: An Individual Patient Data Meta-AnalysisJournal of Clinical Oncology, 2012
- CCL2, Galectin-3, and SMRP Combination Improves the Diagnosis of Mesothelioma in Pleural EffusionsJournal of Thoracic Oncology, 2012
- Diagnostic and Prognostic Value of Soluble Mesothelin-Related Proteins in Patients with Malignant Pleural Mesothelioma in Comparison with Benign Asbestosis and Lung CancerJournal of Thoracic Oncology, 2008
- Soluble Mesothelin-Related Peptide Level Elevation in Mesothelioma Serum and Pleural EffusionsThe Annals of Thoracic Surgery, 2008
- Soluble Mesothelin–Related Peptides in the Diagnosis of Malignant Pleural MesotheliomaAmerican Journal of Respiratory and Critical Care Medicine, 2006
- Tumor Markers in Detection of Lung Cancer2006
- Pathological anatomy and molecular pathologyLung Cancer, 2004
- Mesothelin-family proteins and diagnosis of mesotheliomaThe Lancet, 2003
- Use of tumor markers for differential diagnosis of mesothelioma and secondary pleural malignanciesClinical Biochemistry, 2000
- Index for rating diagnostic testsCancer, 1950